If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Succinate-Q oxidoreductase, also known as complex II or succinate dehydrogenase, is a second entry point to the electron transport chain. It is unusual because it is the only enzyme that is part of both the citric acid cycle and the electron transport chain. Complex II consists of four protein subunits and contains a bound flavin adenine dinucleotide (FAD) cofactor, iron–sulfur clusters, and a heme group that does not participate in electron transfer to coenzyme Q, but is believed to be important in decreasing production of reactive oxygen species. It oxidizes succinate to fumarate and reduces ubiquinone. As this reaction releases less energy than the oxidation of NADH, complex II does not transport protons across the membrane and does not contribute to the proton gradient.
Data from the Office for National Statistics indicates that the average annual increase in employee earnings (excluding bonuses) was 6.2%, using data from the final three months of 2023. 14 February Office for National Statistics data shows that UK inflation remained at 4% in January 2024, despite a slight fall in food prices and a rise in energy prices. Train drivers' union ASLEF announces that drivers at five train operators – Chiltern, c2c, East Midlands, Northern and TransPennine – have voted for a further six months of industrial action. Food delivery drivers with companies including Uber Eats, Just Eat and Deliveroo stage a five-hour strike between 5pm and 10pm over pay and conditions. 15 February The UK is confirmed to be in a recession, after the economy shrank by 0.3% between October and December, having already contracted between July and September 2023. The new names of London's six Overground lines are revealed, with significant changes to the look of the famous Tube map set to take place. From September the six lines will be known as Lioness, Mildmay, Windrush, Weaver, Suffragette and Liberty. 16 February 2024 Wellingborough by-election: Labour's Gen Kitchen takes the Conservative Peter Bone's former seat, which he had held with a majority of more than 18,000. The swing of 28.5% is the second largest swing from Conservative to Labour at a by-election since the Second World War. 2024 Kingswood by-election: Labour's Damien Egan overturns an 11,220 Conservative majority to win Conservative Chris Skidmore's former seat.
A glycoprotein is a compound containing carbohydrate (or glycan) covalently linked to protein. The carbohydrate may be in the form of a monosaccharide, disaccharide(s), oligosaccharide(s), polysaccharide(s), or their derivatives (e.g. sulfo- or phospho-substituted). One, a few, or many carbohydrate units may be present. Proteoglycans are a subclass of glycoproteins in which the carbohydrate units are polysaccharides that contain amino sugars. Such polysaccharides are also known as glycosaminoglycans.
In addition to actions at receptors, Semax, as well as a related peptide drug, Selank, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides (IC50 = 10 μM), though the clinical significance of this property is uncertain. As a peptide, Semax has poor oral bioavailability and hence is administered parenterally as a nasal spray or subcutaneous injection.
Sources: en.wikipedia.org
1993/1747) A35 Trunk Road (Tolpuddle to Puddletown Bypass) (Detrunking) Order 1993 (S.I. 1993/1748) Environmental Protection (Prescribed Processes and Substances) (Amendment) Regulations 1993 (S.I. 1993/1749) Northern Ireland Act 1974 (Interim Period Extension) Order 1993 (S.I. 1993/1753) Social Security (Unemployment, Sickness and Invalidity Benefit) Amendment Regulations 1993 (S.I. 1993/1754) Education (School Teachers' Pay and Conditions) (No. 2) Order 1993 (S.I. 1993/1755) Civil Legal Aid (General) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1756) North Circular Trunk Road (A406) and A1400 Trunk Road (Waltham Forest and Redbridge) (Speed Limits) Order 1993 (S.I. 1993/1757) Road Vehicles (Registration and Licensing) (Amendment) Regulations (Northern Ireland) 1993 (S.I. 1993/1759) Road Vehicles (Registration and Licensing) (Amendment) Regulations 1993 (S.I. 1993/1760) Bradford Community Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1761) Bradford Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1762) Chesterfield and North Derbyshire Royal Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1763) Doncaster Royal Infirmary and Montagu Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1764) Eastbourne and County Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1765) Northern Devon Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
== Medical uses == People diagnosed with trypanosome-caused disease should be treated with an anti-trypanosomal. Treatment is based on stage, 1 or 2, and parasite, T. b. rhodesiense or T. b. gambiense. In stage 1 disease, trypanosomes are present only in the peripheral circulation. In stage 2 disease, trypanosomes have crossed the blood-brain barrier and are present in the central nervous system. The following are considerable treatment options: Melarsoprol is a treatment used during the second stage of the disease. So far, it is the only treatment available for late-stage T. b. rhodesiense. Due to high toxicity, melarsoprol is reserved only for the most dangerous cases. Other agents associated with lower toxicity levels are used during stage 1 of the disease. The approval of the nifurtimox-eflornithine combination therapy (NECT) in 2009 for the treatment of T. b. gambiense limited the use of melarsoprol to the treatment of second-stage T. b. rhodesiense. Failure rates of 27% in certain African countries have been reported. This was caused by both drug resistance and additional mechanisms that have not yet been elucidated. Resistance is likely due to transport problems associated with the P2 transporter, an adenine-adenosine transporter. Resistance can occur with point mutations within this transporter. Resistance has been present since the 1970s. In August 2024, the World Health Organization recommended fexinidazole, developed by the Drugs for Neglected Diseases initiative and partners to replace melarsoprol as the first-line treatment for sleeping sickness caused by T.
=== Small RNA molecules regulate gene expression by post-transcriptional gene silencing === Another previously unknown mechanism by which RNA molecules are involved in genetic regulation was discovered in the 1990s. Small RNA molecules termed microRNA (miRNA) and small interfering RNA (siRNA) are abundant in eukaryotic cells and exert post-transcriptional control over mRNA expression. They function by binding to specific sites within the mRNA and inducing cleavage of the mRNA via a specific silencing-associated RNA degradation pathway.
The Appalachian Mountains contain major deposits of anthracite coal as well as bituminous coal. In the folded mountains the coal is in metamorphosed form as anthracite, represented by the Coal Region of northeastern Pennsylvania. The bituminous coal fields of western Pennsylvania, western Maryland, southeastern Ohio, eastern Kentucky, southwestern Virginia, and West Virginia contain the sedimentary form of coal. The mountain top removal method of coal mining, in which entire mountain tops are removed, is currently threatening vast areas and ecosystems of the Appalachian Mountain region. The surface coal mining that started in the 1940s has significantly impacted the central Appalachian Mountains in Kentucky, Tennessee, Virginia and West Virginia. Early mining methods were unregulated and mined land reclamation research, including acid base accounting, was led by the West Virginia University in the 1960s and 1970s. West Virginia developed rigorous mine reclamation standards for state coal mines in the late 1960s. Regulations were introduced by most states to protect the Appalachian Mountains by the late 1960s. Social and political activism brought about the Surface Mining Control and Reclamation Act of 1977. The 1859 discovery of commercial quantities of petroleum in the Appalachian Mountains of western Pennsylvania started the modern United States petroleum industry. Recent discoveries of commercial natural gas deposits in the Marcellus Shale formation and Utica Shale formations have once again focused oil industry attention on the Appalachian Basin.
== Surveillance == Comparitech Limited, a UK technology advisor, published "The world's most-surveilled cities" in August 2019. It assembled data on the number of closed-circuit television (CCTV) cameras installed in 120 global cities. It then ranked the cities by number of cameras per 1,000 inhabitants. China's cities were found to be the most surveilled. Bangkok was ranked 31 (1=most surveilled; 120=least surveilled), with an estimated 53,429 cameras installed, or 5.16 cameras per 1,000 inhabitants. Other ASEAN cities were ranked: Singapore, 11 (86,000 cameras); Ho Chi Minh City, 72 (6,150 cameras); Yangon, 76 (2,995 cameras); Jakarta, 77 (6,000 cameras); Hanoi, 79 (4,400 cameras); Kuala Lumpur, 106, (1,000 cameras).
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.